Esperion Therapeutics Inc (NAS:ESPR)
$ 2.8 0.33 (13.36%) Market Cap: 530.49 Mil Enterprise Value: 572.87 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 55/100

Esperion Therapeutics and Oberland Capital Management LLC Revenue-Based Funding Agreement - Conference Call Transcript

Jun 26, 2019 / 08:30PM GMT
Release Date Price: $48.63 (-0.78%)
Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Oberland Capital-Esperion Revenue-Based Funding Agreement Call. (Operator Instructions)

Now it's my pleasure to turn the call to Alex Schwartz, Head of Investor Relations.

Alexander Duke Schwartz
Esperion Therapeutics, Inc. - Senior Director of IR

Thank you, Carmen. Good afternoon, everyone, and thank you, for joining us. With me today from Esperion are Tim Mayleben, President and Chief Executive Officer; Rick Bartram, Chief Financial Officer; and Mark Glickman, Chief Commercial Officer.

I'd like to remind callers that the information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risk and uncertainties associated with the business.

These forward-looking statements are qualified in their entirety

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot